Botulinum Toxin for the Treatment of Tremor and Tics

Abstract

The therapeutic applications of botulinum toxin (BoNT) have grown manifold since its initial approval in 1989 by the U.S. Food and Drug Administration for the treatment of strabismus, blepharospasm, and other facial spasms. Although it is the most potent biologic toxin known to man, long-term studies have established its safety in the treatment of a variety of neurologic and nonneurologic disorders. Despite a paucity of randomized controlled trials, BoNT has been found to be beneficial in treating a variety of tremors and tics when used by clinicians skilled in the administration of the drug for these hyperkinetic movement disorders. Botulinum toxin injections can provide meaningful improvement in patients with localized tremors and tics; in some cases, they may be an alternative to other treatments with more undesirable adverse effects.

Keywords

botulinum toxin - essential tremor - tremor - tics

• References

• 1 Ramirez-Castaneda J, Jankovic J. Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon 2014; 90 (0) 344-348
• 2 Ramirez-Castaneda J, Jankovic J. Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel) 2013; 5 (2) 249-266
• 3 Elias WJ, Shah BB. Tremor. JAMA 2014; 311 (9) 948-954
• 4 Jankovic J, Tolosa E. Parkinson's Disease and Movement Disorders. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2015: 278-297
• 5 Mostile G, Fekete R, Giuffrida JP , et al. Amplitude fluctuations in essential tremor. Parkinsonism Relat Disord 2012; 18 (7) 859-863
• 6 Voller B, Lines E, McCrossin G , et al. Alcohol challenge and sensitivity to change of the Essential Tremor Rating Assessment Scale. Mov Disord 2014; 29 (4) 555-558
• 7 Rincon F, Louis ED. Benefits and risks of pharmacological and surgical treatments for essential tremor: disease mechanisms and current management. Expert Opin Drug Saf 2005; 4 (5) 899-913
• 8 Jankovic J, Schwartz K. Botulinum toxin treatment of tremors. Neurology 1991; 41 (8) 1185-1188
• 9 Trosch RM, Pullman SL. Botulinum toxin A injections for the treatment of hand tremors. Mov Disord 1994; 9 (6) 601-609
• 10 Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord 1996; 11 (3) 250-256
• 11 Brin MF, Lyons KE, Doucette J , et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001; 56 (11) 1523-1528
• 12 Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon 2009; 54 (5) 614-623
• 13 Jankovic J. The use of botulinum toxin in tic disorders and essential hand and head tremor. In: Manual of Botulinum Toxin Therapy. 2nd ed. New York: Cambridge University Press; 2013: 160-167
• 14 ClinicalTrials.gov. Botulinum toxin A to treat arm tremor. 2015. Available at: https://clinicaltrials.gov/ct2/show/study/NCT02207946 Accessed June 30, 2015
• 15 Zesiewicz TA, Shaw JD, Allison KG, Staffetti JS, Okun MS, Sullivan KL. Update on treatment of essential tremor. Curr Treat Options Neurol 2013; 15 (4) 410-423
• 16 Hallett M, Albanese A, Dressler D , et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 2013; 67: 94-114
• 17 Louis ED. Medication non-adherence in essential tremor. Parkinsonism Relat Disord 2015; 21 (2) 138-141
• 18 Pahwa R, Busenbark K, Swanson-Hyland EF , et al. Botulinum toxin treatment of essential head tremor. Neurology 1995; 45 (4) 822-824
• 19 Fasano A, Bove F, Lang AE. The treatment of dystonic tremor: a systematic review. J Neurol Neurosurg Psychiatry 2014; 85 (7) 759-769
• 20 Jankovic J. Essential tremor: clinical characteristics. Neurology 2000; 54 (11) (Suppl. 04) S21-S25
• 21 Louis ED, Ford B, Barnes LF. Clinical subtypes of essential tremor. Arch Neurol 2000; 57 (8) 1194-1198
• 22 Sulica L, Louis ED. Clinical characteristics of essential voice tremor: a study of 34 cases. Laryngoscope 2010; 120 (3) 516-528
• 23 Gurey LE, Sinclair CF, Blitzer A. A new paradigm for the management of essential vocal tremor with botulinum toxin. Laryngoscope 2013; 123 (10) 2497-2501
• 24 Baizabal-Carvallo JF, Cardoso F, Jankovic J. Myorhythmia: phenomenology, etiology, and treatment. Mov Disord 2015; 30 (2) 171-179
• 25 Pearce JM. Palatal myoclonus (syn. palatal tremor). Eur Neurol 2008; 60 (6) 312-315
• 26 Penney SE, Bruce IA, Saeed SR. Botulinum toxin is effective and safe for palatal tremor: a report of five cases and a review of the literature. J Neurol 2006; 253 (7) 857-860
• 27 Thenganatt MA, Jankovic J. Psychogenic tremor: a video guide to its distinguishing features. Trem Oth Hyperkin Mov (N.Y.) 2014; 4: 253
• 28 Bain PG, Findley LJ, Britton TC , et al. Primary writing tremor. Brain 1995; 118 (Pt 6) 1461-1472
• 29 Espay AJ, Hung SW, Sanger TD, Moro E, Fox SH, Lang AE. A writing device improves writing in primary writing tremor. Neurology 2005; 64 (9) 1648-1650
• 30 Papapetropoulos S, Singer C. Treatment of primary writing tremor with botulinum toxin type a injections: report of a case series. Clin Neuropharmacol 2006; 29 (6) 364-367
• 31 Diamond A, Jankovic J. Treatment of advanced Parkinson's disease. Expert Rev Neurother 2006; 6 (8) 1181-1197
• 32 Pullman SL, Greene P, Fahn S, Pedersen SF. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch Neurol 1996; 53 (7) 617-624
• 33 Henderson JM, Ghika JA, Van Melle G, Haller E, Einstein R. Botulinum toxin A in non-dystonic tremors. Eur Neurol 1996; 36 (1) 29-35
• 34 Rahimi F, Bee C, Debicki D, Roberts AC, Bapat P, Jog M. Effectiveness of BoNT A in Parkinson's disease upper limb tremor management. Can J Neurol Sci 2013; 40 (5) 663-669
• 35 Schneider SA, Edwards MJ, Cordivari C, Macleod WN, Bhatia KP. Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson's disease. Mov Disord 2006; 21 (10) 1722-1724
• 36 Tarsy D, Ro SI. Unusual position-sensitive jaw tremor responsive to botulinum toxin. Mov Disord 2006; 21 (2) 277-278
• 37 Holmes G. On certain tremors in organic cerebral lesions. Brain 1904; 27: 327-375
• 38 Vélez M, Cosentino C, Torres L. Levodopa-responsive rubral (Holmes') tremor. Mov Disord 2002; 17 (4) 741-742
• 39 Ahn SY, Kim DA, Park YO, Shin JH. Effect of ultrasonography-guided botulinum toxin type a injection in holmes' tremor secondary to pontine hemorrhage: case report. Ann Rehabil Med 2014; 38 (5) 694-697
• 40 Pittock SJ, McClelland RL, Mayr WT, Rodriguez M, Matsumoto JY. Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population. Mov Disord 2004; 19 (12) 1482-1485
• 41 Mehanna R, Jankovic J. Movement disorders in multiple sclerosis and other demyelinating diseases. J Neurol Sci 2013; 328 (1–2) 1-8
• 42 Koch M, Mostert J, Heersema D, De Keyser J. Tremor in multiple sclerosis. J Neurol 2007; 254 (2) 133-145
• 43 Van Der Walt A, Sung S, Spelman T , et al. A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor. Neurology 2012; 79 (1) 92-99
• 44 Schneider SA, Deuschl G. Medical and surgical treatment of tremors. Neurol Clin 2015; 33 (1) 57-75
• 45 Bandmann O, Weiss KH, Kaler SG. Wilson's disease and other neurological copper disorders. Lancet Neurol 2015; 14 (1) 103-113
• 46 Krauss JK, Jankovic J. Head injury and posttraumatic movement disorders. Neurosurgery 2002; 50 (5) 927-939 , discussion 939–940
• 47 Kitagawa M, Murata J, Kikuchi S , et al. Deep brain stimulation of subthalamic area for severe proximal tremor. Neurology 2000; 55 (1) 114-116
• 48 Kim SD, Yiannikas C, Mahant N, Vucic S, Fung VS. Treatment of proximal upper limb tremor with botulinum toxin therapy. Mov Disord 2014; 29 (6) 835-838
• 49 Latino P, Pellicano C, Pontieri FE, Giovannelli M. Treatment with botulinum toxin for anti-MAG neuropathy-related arm tremor. Neurol Sci 2015; 36 (2) 333-334
• 50 Jankovic J, Kurlan R. Tourette syndrome: evolving concepts. Mov Disord 2011; 26 (6) 1149-1156
• 51 Scahill L, Chappell PB, Kim YS , et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158 (7) 1067-1074
• 52 Gilbert DL, Jankovic J. Pharmacological treatment of Tourette syndrome. J Obsessive-Compulsive Relat Disord 2014; 3 (4) 407-414
• 53 Wijemanne S, Wu LJ, Jankovic J. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord 2014; 29 (1) 126-130
• 54 Jankovic J. Therapeutic developments for tics and myoclonus. Mov Disord 2015; 30 (11) 1566-1573
• 55 Jankovic J. Botulinum toxin in the treatment of dystonic tics. Mov Disord 1994; 9 (3) 347-349
• 56 Patel N, Jankovic J, Hallett M. Sensory aspects of movement disorders. Lancet Neurol 2014; 13 (1) 100-112
• 57 Kwak CH, Hanna PA, Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol 2000; 57 (8) 1190-1193
• 58 Marras C, Andrews D, Sime E, Lang AE. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 2001; 56 (5) 605-610
• 59 Vincent Jr DA. Botulinum toxin in the management of laryngeal tics. J Voice 2008; 22 (2) 251-256
• 60 Porta M, Maggioni G, Ottaviani F, Schindler A. Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A. Neurol Sci 2004; 24 (6) 420-423
• 61 Singer C, Papapetropoulos S, Spielholz F, Schindler NI. Primary writing tremor: report of a case successfully treated with botulinum toxin A injections and discussion of underlying mechanism. Mov Disord 2005; 20 (10) 1387-1388